

THRU ONLINE FILING

December 19, 2024

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Kind Attention : Mr. Binoy Yohannan, Associate Vice President, Surveillance

Dear Sir,

Sub: Increase in Volume

We refer to your letter under Ref. No. : NSE/CM/Surveillance/15105 dt. December 18, 2024 regarding your noticing significant increase in the trading volume of Company's securities across exchanges.

In this regard, we wish to inform you that the Company has no information or announcement (including impending announcement) which in our opinion will have a bearing on the price / volume behavior in the Company's scrip.

With respect to the traded volume of the Company's scrip, we wish to inform you that one of the Promoter / Promoter Group shareholder of the Company, Mrs. Usha M. Chandurkar has sold 40,00,000 equity shares of the Company on BSE on 18th December, 2024. The necessary disclosure in respect of this sale transaction has been given by the Company / Seller to the stock exchanges today under the relevant provisions of the SEBI (PIT) Regulations and SEBI (SAST) Regulations.

Thanking you

Yours faithfully
For Ipca Laboratories Limited

Harish Kamath
Corporate Counsel & Company Secretary

Ipca Laboratories Ltd.

www.ipca.com

125, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6210 5000 F: +91 22 6210 5005

Regd. Office: 48, Kandivli Industrial Estate, Kandivli (West), Mumbai 400 067 (Maharashtra), India | T: +91 22 6647 4444

E: ipca@ipca.com CIN: L24239MH1949PLC007837